Skip to main content
SpringerLink
Log in

Relationship of P-glycoprotein and p53 protein to chemosensitivity in colorectal cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Resistance of tumors to chemotherapeutic agents is a major problem in cancer treatment. Recent advances in molecular biology have shown a role for oncogenes in this resistance.

Methods

We determined the positive or negative expression of P-glycoprotein and mutant p53 protein by immunohistochemistry on 101 human colorectal cancer and correlated the expression of these proteins with the chemosensitivity of the tumors to various anticancer agents using the succinate dehydrogenase inhibition (SDI) test.

Results

Fifty-five (54.5%) of 101 tumors expressed P-glycoprotein and 53 (52.5%) expressed a mutant p53 protein. Thirty-seven of 55 tumors positive for P-glycoprotein also expressed a mutant p53 protein. The association between the coexpression of P-glycoprotein and p53 protein was statistically significant (P=0.001). Neither the expression of P-glycoprotein nor p53 protein affected the chemosensitivity of the tumor to doxorubicin hydrochloride, aclarubicin hydrochloride, pirarubicin, epirubicin hydrochloride, mitomycin C, 5-fluorouracil, cisplatin, carboplatin, or etoposide. However, a positive correlation was found between the control optical density and chemosensitivity in the P-glycoprotein or mutant p53 protein negative tumors. Oppositely, some P-glycoprotein or mutant p53 protein positive tumors showed low chemosensitivity in spite of their high control optical density.

Conclusions

A highly statistically significant coexpression of P-glycoprotein and mutant p53 protein was found in colorectal cancer. Furthermore, differences in cell growth between the tumor samples indicate the possibility that the expression of P-glycoprotein and mutant p53 protein in colorectal cancer tumors could be associated with chemoresistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scotto KW, Biedler JL, Melera PW. Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 1986;232:751–755.

    PubMed  CAS  Google Scholar 

  2. Van der Bliek AM, Van der Velde-Koerts T, Ling V, Borst P. Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol 1986;6:1671–1678.

    PubMed  Google Scholar 

  3. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265–269.

    Article  PubMed  CAS  Google Scholar 

  4. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985;316:820–823.

    Article  PubMed  CAS  Google Scholar 

  5. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388–1393.

    Article  PubMed  CAS  Google Scholar 

  6. Rutledge ML, Robey-Cafferty SS, Silva EG, Bruner JM. Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Mod Pathol 1990;3:298–301.

    PubMed  CAS  Google Scholar 

  7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84: 7735–7738.

    Article  PubMed  CAS  Google Scholar 

  8. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicine, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004–3008.

    Article  PubMed  CAS  Google Scholar 

  9. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459–462.

    PubMed  CAS  Google Scholar 

  10. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994;86:850–855.

    PubMed  CAS  Google Scholar 

  11. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720–2726.

    PubMed  CAS  Google Scholar 

  12. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutation in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555–7559.

    Article  PubMed  CAS  Google Scholar 

  13. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991;138:807–813.

    PubMed  CAS  Google Scholar 

  14. Van den Berg FM, Tigges AJ, Schipper MEI, Den Hartog-Jager FCA, Kroes WGM, Walboomers JMM. Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989;157:193–199.

    Article  PubMed  Google Scholar 

  15. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;83:111–116.

    PubMed  CAS  Google Scholar 

  16. Yamauchi M, Kumazawa H, Satta T, Sugawara I, Isobe K, Kodera Y, Ito K, Watanabe T, Takagi H. Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur J Cancer 1992;28A:1422–1427.

    Article  PubMed  CAS  Google Scholar 

  17. Orita H, Maehara Y, Anai H, Baba H, Kusumoto H, Korenaga D, Sugimati K. Expression of P-glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas. Seminars in Surgical Oncology 1994;10:135–139.

    PubMed  CAS  Google Scholar 

  18. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985;3:311–315.

    PubMed  CAS  Google Scholar 

  19. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992;151:237–244.

    Article  PubMed  CAS  Google Scholar 

  20. Hsu SM, Raine L, Fanger H. Use of Avidine-Biotin-Peroxidase complex (ABC) in immunoperoxidase technique: a comparison between A-B-C and unlabeled antibody (PAP) procedure. J Histochem Cytochem 1981;29: 577–583.

    PubMed  CAS  Google Scholar 

  21. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936–942.

    PubMed  CAS  Google Scholar 

  22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.

    Article  PubMed  CAS  Google Scholar 

  23. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH. Chemosensitivity testing of human solid tumors: a review of 1582 assays with 258 clinical correlations. Cancer 1984;53:1240–1245.

    Article  PubMed  CAS  Google Scholar 

  24. Weinstein RS, Kuszak JR, Jakate SM, Lebovitz MD, Kluskens LF, Coon JS. ABO blood type predicts the cytolocalization of anti-P-glycoprotein monoclonal antibody reactivity in human colon and ureter. Hum Pathol 1990;21:949–958.

    Article  PubMed  CAS  Google Scholar 

  25. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531–539.

    PubMed  CAS  Google Scholar 

  26. Wada Y, Tomiyoshi Y, Fujimaru J, Ogura M, Yoshida S, Takeda Y. Sensitivity test of anti-tumor agents. 2. Application of MTT assay. Jpn J Cancer Chemother 1991; 18:1587–1592.

    CAS  Google Scholar 

  27. Asanuma F, Yamada Y, Kawamura E, Kurokawa T, Lee KE, Yamada T. Comparison between clinical response and in vitro chemosensitivity of solid tumors in the succinic dehydrogenase inhibition test. Jpn J Cancer Chemother 1992;19:95–101.

    CAS  Google Scholar 

  28. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Res 1988;48:3595–3602.

    PubMed  CAS  Google Scholar 

  29. Ramu A, Pollard HB, Rosario LM. Doxorubicin resistance in P388 leukemia—evidence for reduced drug influx. Int J Cancer 1989;44:539–547.

    PubMed  CAS  Google Scholar 

  30. Lowe SW, Ruley HE, Jacks T, Housman DE. p53 dependent apoptosis modulates the cytotoxity of anticancer agents. Cell 1993;74:957–967.

    Article  PubMed  CAS  Google Scholar 

  31. Fan S, EL-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath JI, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824–5830.

    PubMed  CAS  Google Scholar 

  32. Bradeley G, Naik M, Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 1989;49:2790–2796.

    Google Scholar 

  33. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazder A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116–124.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Surgery, University of Tokushima School of Medicine, 3-18 Kuramoto-cho, 770, Tokushima, Japan

    Keiko Yagi, Kazufumi Kunitomo & Seiki Tashiro

  2. First Department of Pathology, University of Tokushima School of Medicine, Tokushima, Japan

    Kunio Ii

Authors
  1. Keiko Yagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazufumi Kunitomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kunio Ii
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seiki Tashiro
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Yagi, K., Kunitomo, K., Ii, K. et al. Relationship of P-glycoprotein and p53 protein to chemosensitivity in colorectal cancer. Int J Clin Oncol 2, 81–91 (1997). https://doi.org/10.1007/BF02488878

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02488878

Key words

Search

Navigation